GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camp4 Therapeutics Corp (NAS:CAMP) » Definitions » FCF Margin %

CAMP (Camp4 Therapeutics) FCF Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Camp4 Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Camp4 Therapeutics's Free Cash Flow for the three months ended in Sep. 2024 was $0.00 Mil. Camp4 Therapeutics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Camp4 Therapeutics's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Camp4 Therapeutics's current FCF Yield % is -51.84%.

The historical rank and industry rank for Camp4 Therapeutics's FCF Margin % or its related term are showing as below:

CAMP' s FCF Margin % Range Over the Past 10 Years
Min: -12809.43   Med: -12809.43   Max: -12809.43
Current: -12809.43


During the past 2 years, the highest FCF Margin % of Camp4 Therapeutics was -12809.43%. The lowest was -12809.43%. And the median was -12809.43%.

CAMP's FCF Margin % is ranked worse than
93.22% of 1018 companies
in the Biotechnology industry
Industry Median: -139.165 vs CAMP: -12809.43


Camp4 Therapeutics FCF Margin % Historical Data

The historical data trend for Camp4 Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camp4 Therapeutics FCF Margin % Chart

Camp4 Therapeutics Annual Data
Trend Dec22 Dec23
FCF Margin %
- -12,809.43

Camp4 Therapeutics Quarterly Data
Dec22 Jun23 Sep23 Dec23 Jun24 Sep24
FCF Margin % Get a 7-Day Free Trial - - - - -

Competitive Comparison of Camp4 Therapeutics's FCF Margin %

For the Biotechnology subindustry, Camp4 Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Camp4 Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camp4 Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Camp4 Therapeutics's FCF Margin % falls into.


;
;

Camp4 Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Camp4 Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-44.833/0.35
=-12,809.43 %

Camp4 Therapeutics's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Camp4 Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Camp4 Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Camp4 Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.